Introduction
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has been extensively used in biochemical analysis, and has become an indispensable tool in proteomics research. [1] [2] [3] The use of an UV-absorbing organic matrix, such as α-cyano-4-hydroxycinnamic acid (CHCA) or 2,5-dihydroxybenzoic acid (DHBA), increases the efficiency of energy transfer from the pulse laser to analytes, resulting in enhancement of the desorption/ionization efficiency, with less fragmentation of the analytes. Despite the success of MALDI-MS, several problems associated with the use of organic matrixes are frequently encountered: (1) matrix optimization, (2) uneven analyte distribution, and (3) matrix interference. In particular, the MALDI-MS spectra have a high chemical background noise in the low-mass region (< m/z 500), due to the formation of clusters of matrix ions or degradation products of the matrix; thus, MALDI-MS is not normally used for the analysis of small molecules.
To solve these problems, surface-assisted laser desorption/ ionization mass spectrometry (SALDI-MS) using inorganic matrixes has been reported; this concept was originally introduced by Tanaka et al., using 30 nm cobalt powder suspensions in glycerol. 1a More recently, the applicability of SALDI has been demonstrated using various nanomaterials (nanoparticles or nanostructured substrates), including carbon-based materials, [4] [5] [6] [7] [8] metal (or metal oxide)-based materials, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and silicon-based materials. [23] [24] [25] [26] [27] [28] [29] These developments in SALDI-MS have occurred in close conjunction with the novel fabrication of nanoparticles (NPs) and nanostructured surfaces in material chemistry and physics. Several review articles on SALDI-MS have been reported. 30 In SALDI-MS (including MALDI-MS), on the other hand, signal suppression from multiple components, such as biological samples, becomes a significant problem. Due to the complexity of serum or urine samples, a pretreatment step is often required to remove proteins, lipids, salts, and other potential interfering components prior to MS analysis. Thus, sample separation and enrichment of target analytes from complex biological samples are important steps towards obtaining good-quality mass spectra. Magnetic NPs have enormous potential for sample pretreatment and enrichment of target analytes, because of their high surface area and their potential functionalization towards the affinity with the analyte of interset. In the next step, target analytes separated by magnetic NPs can be identified by directly introducing the particles into the mass spectrometer for SALDI-MS analysis without the elution process of analytes (affinity-SALDI-MS). Thus, affinity SALDI-MS using magnetic NPs would have advantages on user-friendliness, throughput improvement, and quantitative analysis. Recently, various nanoparticles have been employed as affinity probes for the extraction of analytes, including laser desorption ionization (LDI)-assisting nanoparticles, such as Au,  10,13,31 Ag, 17,32,33 TiO2, 34  iron oxides, 11, 35 CdSe, 19 FePtCu, 36 and carbon nanotubes.
Here, we report on the use of human serum albumin (HSA)-modified Fe3O4 nanoparticles (NPs) (HSA-Fe3O4 NPs) for affinity-SALDI-MS of small drugs in human biological liquids. We demonstrated that HSA-Fe3O4 NPs effectively captured small drugs from human urine and serum via the interactions between HSA and these drugs. The drugs adsorbed on HSA could then be identified by directly introducing the HSA-Fe3O4 NPs into a mass spectrometer for SALDI-MS analysis. The ability of HSA to interact with multiple small drugs facilitated the simultaneous detection of a 4-drug-mixture in serum, viz., phenytoin, ibuprofen, camptothecin, and warfarin sodium, by affinity-SALDI-MS using HSA-Fe3O4 NPs. In contrast, matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) with an organic matrix could detect only warfarin sodium. We also demonstrated the capacity of affinity-SALDI-MS to quantify warfarin sodium in urine samples across a range of 50 -1000 μM (R 2 = 0.998) when using HSA-Fe3O4 NPs. The detection sensitivity was further improved to a range of 5 -100 μM (R 2 = 0.999) by using denatured HSA. The open structure of denatured HSA may enhance the effective extraction of small drugs from biological liquids, and increase the detection-sensitivity of affinity-SALDI-MS. Affinity-SALDI-MS using protein-modified Fe3O4 NPs can open up new approaches to the analytical detection of small drugs in biological liquids by SALDI-MS. Among these NPs, iron-based magnetic NPs can be used as a quick and simple method for the efficient and reliable capture of target analytes in biological fluids.
Most iron-based magnetic NPs currently used are super-paramagnetic, i.e., they can be magnetized by an external magnetic field and immediately re-dispersed once the magnet is removed. 38 Surface modification of magnetic NPs to create affinity for the analyte of interests is one of the keys for effective extraction of the target analyte from complex biological fluids using magnetic NPs. Various surface modifications of magnetic NPs have been reported, such as the addition of amines, carboxylic acid, thiols, and hydroxyls to the surface to allow the extraction of a target analyte from complex mixtures. However, affinity-SALDI-MS using NPs in biological liquids (e.g., serum and urine) remains challenging, due to interference from various components in the sample and the need for high sensitivity detection of low-abundance analytes. 39, 40 One of the very few reports on SALDI-MS using the protein-small molecular interaction exists in a protein-modified porous silicon by Hu et al. , 26 who applied protein-modified porous silicon for the detection of small molecules through small molecule-protein interactions using desorption/ionization on porous silicon mass spectrometry (DIOS-MS). Unfortunately, the detection limit of small molecules was not shown, and there was no application for the detection of small molecules in biological liquids, such as serum or urine. In this study, we focused on the surface modification of magnetic NPs using human serum albumin (HSA) for affinity-SALDI-MS. HSA is the most abundant plasma protein, and has exceptional binding capacity for both endogenous and exogenous substances, including a wide range of drugs. 41 The binding of small drugs to HSA occurs via both 2 well-characterized binding on the HSA molecule (i.e., site I and site II) and non-specific binding. [42] [43] [44] [45] [46] On the basis of the binding capacity of HSA for various small drugs, an HSA-based high-performance liquid chromatographic (HPLC) column has been developed as a tool to investigate HSA-drug interactions. [47] [48] [49] Thus, we hypothesized that SALDI-MS using HSA-modified Fe3O4 NPs (HSA-Fe3O4 NPs) would be useful for the extraction of small drugs from complex biological fluids via HSA-small drug interactions. It is important to examine the presence or absence of drugs or their metabolites in blood or urine after administration to a human for any pharmacological effect. For example, warfarin is a coumarin derivative used as an oral anticoagulant drug in the treatment and prevention of thromboembolism. The pharmacological effect depends on the blood concentration of warfarin. We demonstrated that HSA-modified Fe3O4 NPs could capture small drugs (warfarin, camptothecin, ibuprofen, and phenytoin) from human urine and serum through the interaction of HSA with the drug molecules. These HSA-adsorbed drugs could be identified by directly introducing the Fe3O4 NPs into the mass spectrometer for SALDI-MS analysis. In addition, this method has made it possible to quantify warfarin in urine through affinity-SALDI-MS. The protein-modified Fe3O4 NPs can open up new approaches to the analytical detection of small drugs in biological liquids by SALDI-MS.
Experimental

Reagents and materials
Ferric chloride hexahydrate (FeCl3·6H2O > 99%), ferrous chloride tetrahydrate (FeCl2·4H2O > 99%), 25% ammonia water, 3-aminepropyltrimethoxysilane (APTMS), 99% HSA, methanol, ethanol, tetrahydrofuran (THF), angiotensin II, citric acid, sodium dihydrogenphosphate dihydrate, disodium hydrogenphosphate, trifluoroacetic acid (TFA), sodium iodide, camptothecin, warfarin sodium, ibuprofen, and phenytoin were purchased from Wako Pure Chemicals Industry, Ltd. (Osaka, Japan). Ammonium citrate dibasic, α-cyano-4-hydroxycinnamic acid (CHCA), 3,4-dihydroxybenzylamine (DHBA), 2 M hydrochloric acid, 1-ethyl-3-(3-dimethylaminepropyl) carbodiimide hydrochloride (EDC), and 98% N-hydroxysuccinimide (NHS) were purchased from Sigma-Aldrich, USA. Human serum samples were purchased from Lonza (MD, USA). Human urine was obtained from a healthy man. All chemicals were used as received, except for methanol, which was dried before use in the silanization process. Milli-Q purified water was used for all experiments.
Synthesis of iron oxide nanoparticles
Fe3O4 NPs with an average particle size of 20 -50 nm were prepared using controlled coprecipitation. 50 Briefly, FeCl3·6H2O (4.5 g), FeCl2·4H2O (1.5 g), and 2 M HCl (12.5 mL) were used to prepare a source of iron by dissolving the respective chemicals in Milli-Q water under vigorous stirring. The coprecipitation of Fe3O4 NPs was carried out in a reactor with mechanical stirring (1000 rpm). N2 gas was used during the reaction to prevent the critical oxidation of Fe3O4 NPs. Black powder was collected by sedimentation with the help of an external magnetic field, and was washed several times with Milli-Q water until stable ferrofluid was obtained.
Surface immobilization of HSA on APTMS-modified Fe3O4 NPs
The HSA-Fe3O4 NPs were prepared according to a previous report. 50 Ethanol (5 mL), ammonium hydroxide (25%; 0.7 mL), and APTMS (80 μL) were added to the dried Fe3O4 NPs (500 mg). The resulting solution was shaken for about 24 h (1200 rpm) at a room temperature. After collection of the Fe3O4 NPs by means of an external magnetic field, the NPs were washed with water several times, and the resulting APTMS-modified Fe3O4 NPs dried for 12 h at room temperature. The surface modification of Fe3O4 NPs with APTMS was confirmed by FT-IR spectroscopy by the absorbances from the -SiO (1200 cm -1 ), -SiOCH2 (1100 cm -1 ), and -NH2 (1600 cm -1 ) (not shown). HSA (5 mg), EDC (5 mg), and NHS (6 mg) were dissolved in a 3 mM phosphate buffer solution. This mixture was added to 10 mg of APTMS-modified Fe3O4 NPs. The mixture was then sonicated for 10 min at 4 C and shaken for 24 h at room temperature. The particles were collected under a strong external magnetic field and washed several times with water. The HSA-Fe3O4 NPs were recovered by applying a magnetic field and re-dispersed in aqueous media for use in SALDI-MS.
Transmission electron microscopy
The size and morphology of the particles were determined by a JEM-1400 transmission electron microscope (TEM; JEOL, Japan).
The specimen was prepared by dispersing the Fe3O4 NPs in Milli-Q water by sonication for 3 min. A drop of well-dispersed supernatant was placed on a carbon-coated 200-mesh copper grid, followed by drying of the sample under ambient conditions.
Fourier transform infrared spectroscopy
Fourier transform infrared (FT-IR) spectra were recorded using a FTIR-4100 spectrometer (JASCO, Japan) with the ZnSe ATR accessory, at a resolution of 4 cm -1 .
Thermal study
Thermo gravimetric analysis (TG) was performed for powder samples (10 mg) under N2 gas, with a heating rate of 10 C/min, up to 500 C, using a thermo-gravimetric analyzer (Rigaku Thermo plus EVO TG8120; Rigaku, Japan).
Powder X-ray diffraction
The phase composition of iron oxide samples was identified by powder X-ray diffraction (XRD; Bruker D2 Phaser Table- top Diffractometer) using Cu-Ka radiation at 30 kV and 10 mA, with a step size of 0.02 (Theta) and step time of 4 s, between 15 and 100 (Theta); data were collected at 25 C.
SALDI-MS
SALDI-MS spectra were acquired in the linear mode on an AXIMA-CFR time-of-flight mass spectrometer (Shimadzu/ Kratos, Manchester, UK), with a pulsed nitrogen laser (λ = 337 nm). The mass spectra of 100 different profiles of a sample spot were averaged. One hundred laser shots were used to acquire the mass spectra. The analyte ions were accelerated at 20 kV under delayed extraction conditions. The 2-layer sample preparation method was employed for SALDI-MS with the HSA-Fe3O4 NPs: the first step was spotting of the NPs solution (0.6 μL, 10 mg/mL), prepared by dispersing NPs in water using a vortex mixer for a few minutes, onto a stainless-steel plate, followed by drying. The second step was typically deposition of a 0.6-μL sample solution onto the plate.
Sample extraction with HSA-Fe3O4 NPs followed by SALDI-MS detection (affinity SALDI-MS)
A schematic summary of affinity-SALDI-MS using HSA-Fe3O4 NPs is shown in Fig. 1 . In short, the HSA-Fe3O4 NPs were used to extract a target drug from biological liquids (serum or urine), followed by MS detection using SALDI-MS. Typically, a 100-μL solution of HSA-Fe3O4 NPs (10 mg/mL) was added to an analyte-spiked aqueous solution of 1 mL, and the concentration of the analyte is shown in the corresponding figure caption. Here, we prepared three kinds of analyte-spiked aqueous solutions: (1) phosphate buffer (dihydrogenphosphate dehydrate (0.2 M):disodium hydrogenphosphate (0.2 M):water at a ratio of 1:3:4 (v/v/v%)), (2) urine, and (3) serum (Step 1, Fig. 1 ). The mixture was vortexed for 1 h (Step 2, Fig. 1 ). The analyte-bound NPs were separated from the supernatant using an external magnetic field (Step 3, Fig. 1 ). The analyte-bound NPs were washed with water 3 times (Steps 3 and 4, Fig. 1 ). In the case of serum samples, the analyte-bound NPs were washed further with a citrate buffer solution (triammonium citrate (50 mM)/citric acid (100 mM), 3:1 (v/v)), since this reduced any background noise in the mass spectra of these samples. Finally, 1 μL of the aqueous solution including the analyte-bound NPs (10 mg/mL) was deposited on a MALDI plate for analysis by SALDI-MS (Step 5, Fig. 1 ). When MALDI-MS was used, the analytes of the NPs on the MALDI plate were analyzed by further addition of an organic matrix, viz., CHCA (10 mg/THF mL) or DHBA (10 mg/THF mL).
To construct calibration curves, a stock solution of warfarin sodium (1 mM) in urine was prepared, which was diluted to a given concentration using urine. The mass spectra of 100 different profiles of a sample spot were averaged. Quantitative analysis of warfarin sodium in urine was carried out by measuring the signal-to-noise (S/N) ratio of the ion peak intensity in the mass spectra. The standard deviation of the calibration curve (i.e., the measure of variance from the average value in a set of data) was estimated for data points from 6 different samples.
Results and Discussion
Characterization of HSA-Fe3O4 NPs
XRD analysis of bare Fe3O4 NPs indicated peaks in the XRD patterns representing the magnetite phase ( Supporting  Information, Fig. S1a ). The TEM image of HSA-Fe3O4 NPs showed that the size distribution of these NPs was broad, ranging from 20 to 50 nm (Fig. 2a) . A surface modification of the NPs using HSA improved the dispersion of the Fe3O4 NPs in water, due to the hydrophilic nature of HSA. The surface modification of Fe3O4 NPs with HSA was confirmed by FT-IR spectroscopy, comparing uncoated Fe3O4 and HSA-Fe3O4 NPs. The most characteristic bands of HSA-Fe3O4 were around 1635 (amide I) and 1522 (amide II) cm -1 , indicative of surface modification of the Fe3O4 NPs with HSA (Fig. 2b) . The amount of HSA bound to the surface of Fe3O4 NPs was estimated to be about 15 wt%, according to the difference in weight between HSA-APTMS-coated Fe3O4 NPs and APTMS-coated Fe3O4 NPs, at 800 C, as established by TG analysis (Supporting Information, Fig. S1b ).
SALDI-MS using HSA-Fe3O4 NPs
We examined the effect of the HSA-surface modification on Fe3O4 NPs to verify the SALDI-MS performance.
The SALDI-MS spectra of angiotensin II obtained using HSA-Fe3O4 NPs and bare Fe3O4 NPs, with citrate buffer as the proton source, are shown in Figs. 3a and 3b . The SALDI-MS spectra show the protonated molecular ion of angiotensin II at m/z 1046 when using both HSA-Fe3O4 NPs and bare Fe3O4 NPs. This indicates that the surface modification of Fe3O4 NPs with HSA (~15 wt%) did not reduce the SALDI performance of Fe3O4 NPs. It is noteworthy that HSA-Fe3O4 NPs can detect the protonated molecular ion of angiotensin II, even without the citrate buffer as the proton source (Fig. 3c) , while bare Fe3O4 NPs cannot do so (Fig. 3d) . We attributed the enhanced protonated ions when using HSA-Fe3O4 NPs to the behavior of the basic and acid amino acids of HSA as proton source. The above result indicates that the HSA-Fe3O4 NPs can act as LDI-assisting NPs, and that the surface modification of the Fe3O4 NPs with HSA (~15 wt%) improves the efficiency of SALDI for peptides.
Extraction of small drugs from urine and serum using HSA-Fe3O4 NPs and their detection by affinity SALDI-MS
In this study, we demonstrated that HSA-Fe3O4 NPs can serve as an affinity probe and enhance the SALDI ability for the MS-detection of these drugs (warfarin, camptothecin, ibuprofen, and phenytoin) via the interaction between the drugs and HSA. Figure 4 shows the SALDI mass spectra of the 4 drug molecules, viz., phenytoin, ibuprofen, camptothecin, and warfarin sodium, extracted from aqueous solutions of phosphate buffer. The chemical structures of these drugs are shown in Fig. 4 -for warfarin sodium. In contrast, there were no signals of these drugs in the mass spectra when using bare Fe3O4 NPs (Fig. 4) . The detection of small drugs by the HSAFe3O4 NPs can be attributed to the interaction between HSA and the drugs through the binding sites on HSA.
To demonstrate the application of this methodology presented here to biological liquids, we further applied affinity-SALDI-MS with HSA-Fe3O4 NPs for the analysis of small drugs in serum or urine. Figure 5 shows the SALDI mass spectra of warfarin sodium in urine or serum, after extraction using HSA-Fe3O4 NPs according to the procedures of Fig. 1 . Irrespective of the presence of numerous interfering components in serum and urine, the SALDI-MS spectra using HSA-Fe3O4 NPs showed the ion peak from warfarin sodium [warfarin-Na] -at m/z 307 (Figs. 5a and 5c ), while the ion peak was barely detectable when using bare Fe3O4 NPs (Figs. 5b and 5d ). To further demonstrate the multiple binding capacity of HSA for small drugs, we applied affinity-SALDI-MS using HSA-Fe3O4 NPs to the simultaneous detection of a 4-drug-mixture (phenytoin, ibuprofen, camptothecin, and warfarin sodium) in human serum. Using affinity-SALDI-MS with HSA-Fe3O4 NPs, all ion peaks for ibuprofen, phenytoin, warfarin sodium, and camptothecin were detected in the mass spectra, at m/z 229, 275, 331, and 349 (Fig. 6a) + , respectively. It should be noted that we were able to detect 4-mix drugs as protonated ions at a time in positive ion mode, while we could not detect all 4-mix drugs in the negative ion mode. Although the concentration of each of these drugs in the serum was the same, the peak intensity of warfarin was much larger than those of the other drugs. Whether the reason for this is the high extraction efficiency or the high ionization efficiency of warfarin is not clear. In addition, there is a possibility about the contribution of both specific and nonspecific bindings of drugs onto the HSA-Fe3O4 NPs. However, the question of the detailed binding location sites of different drugs toward HSA in the HSA-Fe3O4 NPs remains unsettled.
We also compared the efficacy of affinity-MALDI-MS (i.e., the use of organic matrix) with that of affinity-SALDI-MS for the simultaneous detection of a 4-drug-mixture in human serum: HSA-Fe3O4 NPs were used to extract a target drug from biological liquids, followed by MS detection by MALDI-MS, with a CHCA or DHBA matrix.
However, the affinity-MALDI-MS was not effective for the detection of the drug mixture from serum. Although the warfarin was detectable, the other drugs were not (Figs. 6b and 6c ). This result indicates the superior performance of affinity-SALDI-MS as an organic matrix-free method for the detection of small drugs in urine or serum.
In order to examine the ability of affinity-SALDI-MS to quantify drugs in biological liquids using HSA-Fe3O4 NPs, a series of warfarin sodium-spiked urine samples were used to evaluate the linearity and the limits of detection (LOD) of the present method. In the affinity-SALDI-MS described herein, the values of the S/N ratios were used to construct an absolute calibration curve of warfarin sodium in urine, without the addition of internal standards, since the reproducibility of curves produced in this way was better than that produced using the ion peak intensities. In the urine samples, a good linear range was obtained, from 50 to 1000 μM (R 2 = 0.998) for HSA-Fe3O4 NPs, as shown in Fig. 7a . The LOD value for warfarin, based on an S/N ratio of 3, was approximately 50 μM for HSA-Fe3O4 NPs.
It has been reported that the urea-induced denaturation of HSA may not lead to an HSA molecule that is fully opened to the solvent, even when using 8 M urea, and that the denaturation of HSA via urea occurs as a single step, involving only the unfolding of sub-domain II of HSA. 51 This may be due to the existence of many intact disulfide bridges in HSA (17 disulfide bridges, in a protein consisting of 585 amino acid residues), which prevent its complete unfolding. In DNaBH4-HSA, the disulfide reduction by NaBH4 induces the cleavage of disulfide bridges, 52 which may also induce further denaturation of HSA, and a change in the interaction of HSA with small drugs, although the detailed denatured structures of DNaBH4-HSA Fe3O4 NP were not clarified in this study. We found that the use of NaBH4-denatured HSA facilitated a higher detection sensitivity in affinity-SALDI-MS.
The denatured HSA-Fe3O4 NPs (DNaBH4-HSA Fe3O4 NPs) were obtained by immersing the HSA-Fe3O4 NPs in 0.1 M NaBH4 aqueous solution for 24 h to reduce S-S bonding in the HSA. The SALDI-MS spectra of warfarin sodium from aqueous solutions of phosphate buffer after extraction of the analyte using (a) HSA-Fe3O4 NPs, and (b) DNaBH4-HSA Fe3O4 NPs are shown in Supporting Information Fig. S2 . The S/N ratio of the ion peak of warfarin sodium could be increased by using DNaBH4-HSA-Fe3O4 NPs. In urine samples, a good linear range was obtained, from 5 to 100 μM (R 2 = 0.999) for DNaBH4-HSA-Fe3O4 NPs, as shown in Fig. 7b . The LOD value for warfarin, based on an S/N ratio of 3, was approximately 5 μM for DNaBH4-HSA-Fe3O4 NPs, which was 10-fold lower than the LOD value (50 μM) for HSA-Fe3O4 NPs. Thus, the use of DNaBH4-HSA-Fe3O4 NPs improved the detection sensitivity of affinity-SALDI MS for warfarin sodium in urine. Although the detailed denatured structures of DNaBH4-HSAFe3O4 NP were not clarified in this study, the open structure of denatured HSA may enhance effective extraction of small drugs from biological liquids via non-specific interaction between DNaBH4-HSA and warfarin sodium, resulting in the increase the detection-sensitivity of affinity-SALDI-MS.
Conclusions
In this study, we demonstrated that HSA-modified Fe3O4 NPs function effectively as affinity probes for the extraction of small drugs, via HSA-small drug interactions, from urea or serum, as well as functioning as LDI-assisting NPs, thereby facilitating affinity-SALDI-MS. By utilizing the ability of HSA to bind multiple small drugs, affinity-SALDI-MS using HSA-Fe3O4 NPs could detect a 4-drug-mixture, viz. phenytoin, ibuprofen, camptothecin, and warfarin sodium, in serum. Effective quantitation in urine was possible across a range of 50 -1000 μM (R 2 = 0.998), when using HSA-Fe3O4 NPs, and across a range of 5 -100 μM (R 2 = 0.999) when using DNaBH4-HSA-Fe3O4 NP. The use of denatured-HSA-Fe3O4 NPs improved the detection sensitivity for warfarin in urine by affinity-SALDI MS by 10-fold, compared to that by using HSA-Fe3O4 NPs. This may be because the open structure of the denatured HSA may improve the efficiency of extracting small drugs from biological liquids and increase the detection sensitivity of affinity-SALDI-MS.
The protein-modified Fe3O4 NPs developed in this study can be changed with various type's proteins, such as avidin, DI-22 antibody, and other proteins. The affinity-SALDI-MS using various type's protein-modified Fe3O4 NPs would extend this method to the analytical detection of various type's small molecules in biological liquids. For the detection of large proteins in biological liquids, on the other hand, the coupling of protein-modified Fe3O4 NPs with MALDI-MS would be useful.
